Gamma glutamyltransferase and metabolic syndrome risk: A systematic review and dose-response meta-analysis

International Journal of Clinical Practice

Volumn 69, Issue 1, 2015, Pages 136-144

  Kunutsor, S K ^a   Apekey, T A ^b   Seddoh, D ^c  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b LEEDS TRINITY UNIVERSITY   (United Kingdom)

^c Maranatha University College   (Ghana)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL EVALUATION; COHORT ANALYSIS; DOSE RESPONSE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; INCIDENCE; META ANALYSIS; METABOLIC SYNDROME X; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; QUALITY CONTROL; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; METABOLISM; PATHOLOGY;

DOSE-RESPONSE RELATIONSHIP, DRUG; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; METABOLIC SYNDROME X; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84920774655     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12507     Document Type: Review

References (33)

1. Expert Panel on Detection Evaluation, Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
2. Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003; 108: 414-9.
3. Lorenzo C, Okoloise M, Williams K, et al. The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study. Diabetes Care 2003; 26: 3153-9.
4. Hunt KJ, Resendez RG, Williams K, et al. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation 2004; 110: 1251-7.
5. Liu Z, Que S, Ning H, et al. Elevated alanine aminotransferase is strongly associated with incident metabolic syndrome: a meta-analysis of prospective studies. PLoS ONE 2013; 8: e80596. doi: 10.1371/journal.pone.0080596.
6. Kunutsor SK, Seddoh D,. Alanine aminotransferase and risk of the metabolic syndrome: a linear dose-response relationship. PLoS ONE 2014; 9: e96068.
7. Liu CF, Zhou WN, Fang NY,. Gamma-glutamyltransferase levels and risk of metabolic syndrome: a meta-analysis of prospective cohort studies. Int J Clin Pract 2012; 66: 692-8.
8. Moher D, Liberati A, Tetzlaff J, Altman DG,. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6: e1000097.
9. Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses, 2011. http://www.ohri.ca/programs/clinical-epidemiology/oxford.asp (accessed 20 August 2012).
10. Greenland S, Longnecker MP,. Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. Am J Epidemiol 1992; 135: 1301-9.
11. Orsini N, Bellocco R, Greenland S,. Generalized least squares for trend estimation of summarized dose-response data. Stata J 2006; 6: 40-57.
12. Harrell FE Jr, Lee KLollock BG,. Regression models in clinical studies: determining relationships between predictors and response. J Natl Cancer 1988; I (80): 1198-202.
13. Chêne G, Thompson SG,. Methods for summarizing the risk associations of quantitative variables in epidemiologic studies in a consistent form. Am J Epidemiol 1996; 144: 610-21.
14. DerSimonian R, Laird N,. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88.
15. Higgins JP, Thompson SG, Deeks JJ, Altman DG,. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-60.
16. Higgins JP, Thompson SG,. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-58.
17. Thompson SG, Sharp SJ,. Explaining heterogeneity in meta-analysis: a comparison of methods. Stat Med 1999; 18: 2693-708.
18. Begg CB, Mazumdar M,. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088-101.
19. Egger M, Davey Smith G, Schneider M, Minder C,. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-34.
20. Alberti KG, Zimmet P, Shaw J,; Group IDFETFC. The metabolic syndrome-a new worldwide definition. Lancet 2005; 366: 1059-62.
21. Fraser A, Harris R, Sattar N, et al. Alanine aminotransferase, gamma-glutamyltransferase, and incident diabetes: the British Women's Heart and Health Study and meta-analysis. Diabetes Care 2009; 32: 741-50.
22. Nakanishi N, Suzuki K, Tatara K,. Serum gamma-glutamyltransferase and risk of metabolic syndrome and type 2 diabetes in middle-aged Japanese men. Diabetes Care 2004; 27: 1427-32.
23. Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease. Diabetes 2001; 50: 1844-50.
24. Hsueh WA, Quinones MJ,. Role of endothelial dysfunction in insulin resistance. Am J Cardiol 2003; 92: 10J-7J.
25. Ruttmann E, Brant LJ, Concin H, et al. Gamma-glutamyltransferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163,944 Austrian adults. Circulation 2005; 112: 2130-7.
26. NACB. Laboratory Guidelines for Screening Diagnosis and Monitoring of Hepatic Injury. Washington, DC: The National Academy of Clinical Biochemistry, 2000.
27. Whitfield JB,. Gamma glutamyl transferase. Crit Rev Clin Lab Sci 2001; 38: 263-355.
28. Emdin Massino C, Michelassi C, et al. Prognostic value of serum gamma-glutamyl transferase activity after myocardial infarction. Eur Heart J 2001; 22: 1802-7.
29. Dhingra R, Gona P, Wang TJ, et al. Serum gamma-glutamyl transferase and risk of heart failure in the community. Arterioscler Thromb Vasc Biol 2010; 30: 1855-60.
30. Gunter EW, Lewis BG, Koncikowski SM,. Laboratory Procedures Used for the Third National Health and Nutrition Examination Survey (NHANES III), 1988-1994. Hyattsville, MD: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Environmental Health, National Center for Health Statistics, 1996.
31. Chitturi S, Abeygunasekera S, Farrell GC, et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002; 35: 373-9.
32. Yadav D, Mahajan S, Subramanian SK, et al. Prevalence of metabolic syndrome in type 2 diabetes mellitus using NCEP-ATPIII, IDF and WHO definition and its agreement in Gwalior Chambal region of Central India. Global J Health Sci 2013; 5: 142-55.
33. Bee YT Jr, Haresh KK, Rajibans S,. Prevalence of metabolic syndrome among Malaysians using the International Diabetes Federation, National Cholesterol Education Program and Modified World Health Organization Definitions. Malays J Nutr 2008; 14: 65-77.